Oxidative Stress in Lung Diseases: Volume 2

A. General Aspects of reactive oxygen species-mediated lung diseases

1. Pathology of lung diseases affected by oxidative stress

3. The state of art of NADPH Oxidase-dependent oxidative stress in lung diseases

4. Effects of radicals on pulmonary surfactant and role of lipid in this scenario

5. Infection induced oxidation and DNA repair

6. Oxidative stress in experimental models of acute lung injury
7. Oxidative Lipidomics of Lung Diseases

B. Chronic lung diseases

8. Oxidative stress in Lung Fibrosis

9. Oxidative Stress Biomarkers in COPD

10. Oxidative stress in emphysema

11. Oxidative stress induced mitochondrial dysfunction and asthma

12. Oxidative stress in asthma and COPD

D. Other lung diseases

13. Oxidative stress in environmental lung diseases

14. Bronchopulmonary dysplasia and oxidative stress in preterm newborns

15. Effect of exogeneous chemical exposure on oxidative stress induced lung diseases

16. Pulmonary antioxidant system in acute and chronic lung injury, pulmonary fibrosis in diabetes

17. Mitochondrial alterations and oxidative stress in cystic fibrosis

E. Prevention and therapeutics

18. Flagellin/Toll-like receptor 5 response was specifically attenuated by keratin sulfate disaccharide via decreased EGFR phosphorylation in human bronchial epithelial cells \

20. ROS: modulator of therapeutic response in non-small cell lung cancer (NSCLC)

21. Arsenic-induced lung injury in rats and its reversal by a garlic polysulfide

22. The Mitochondria-targeted Drugs for Protection of Lung Damage and Pulmonary Diseases .

23. The use of ozone as redox modulator in the treatment of chronic pulmonary disease (COPD)

24. Oxidative stress and therapeutic development in lung cancer

25.The state of art of NADPH Oxidase-dependent oxidative stress in lung diseases.

27. Flagellin/Toll-like receptor 5 response was specifically attenuated by keratin sulfate disaccharide via decreased EGFR phosphorylation in human bronchial epithelial cells.

28. Oxidative stress in experimental models of acute lung injury.

29. Pharmacokinetics, pharmacodynamics and safety of ISO1957, a preclinical candidate possessing activity against infection.

30. Rho kinase as a therapeutic target in pulmonary vascular diseases.

32. Phosgene induced lung damage and its amelioration by cAMP elevating compounds.